Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulse Dosed Ceftriaxone for Post-Treatment Lyme Disease
NCT06785402Phase 2Withdrawn
- Sponsor
- Hackensack Meridian Health
- Start
- May 2026
- Primary completion
- May 2026
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of ceftriaxone in post-treatment Lyme disease syndrome (PTLDS), sponsored by Hackensack Meridian Health. Planned start May 2026; status: withdrawn.
02
Drugs
ceftriaxone
03
Conditions
post-treatment Lyme disease syndrome (PTLDS)
Beyond the preview
Go deeper on NCT06785402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06785402.